Topics

Relapsed Chronic Lymphocytic Leukemia Pipeline Review2023 [Published by First View Insight] Prices from USD $1063

09:54 EST 11 Feb 2020 | BioPortfolio Reports

Firstview Insight's Relapsed Chronic Lymphocytic Leukemia Pipeline Review2023 provides an overview of the pipeline landscape of Relapsed Chronic Lymphocytic Leukemia It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Refractory CLL defined by nonresponse to treatment or relapse/progression within 6 months is associated with multiple unfavourable prognostic factors such as p53 pathway disruption, deteriorating patient condition, increased risk of severe infections, and poor response to treatment, resulting in a very short overall survival. Therefore, refractory CLL represents a highly challenging situation for the hematologist as well as the patient. The amount and quality of data on refractory CLL are rather limited as clinical trials usually combine patients with relapsed and refractory disease. Therapeutic options for refractory CLL include alemtuzumab, ofatumumab, fludarabine and bendamustinebased regimens, platinumbased aggressive protocols and highdose corticosteroids combined with monoclonal antibodies.

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.


Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.


Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.


Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial


Scope

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from preregistration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year


Reasons To Buy

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies

Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration


List of products

Venclyxto

Zydelig

acalabrutinib

AT7519

CC122

AGS67E

BI836826

Monalizumab

JCAR014

Original Article: Relapsed Chronic Lymphocytic Leukemia Pipeline Review2023 [Published by First View Insight] Prices from USD $1063

NEXT ARTICLE

More From BioPortfolio on "Relapsed Chronic Lymphocytic Leukemia Pipeline Review2023 [Published by First View Insight] Prices from USD $1063"

Quick Search